– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Pharmaceutical Technology on MSN
Eisai seeks PMDA approval for subcutaneous Leqembi in Japan
If approved, patients could self-administer a weekly dose at home as an alternative to hospital intravenous dosing.
Most people know the feeling of getting a shot and having your arm feel sore for several days afterward. Some might even expect it as a side effect. The soreness happens when medications are injected ...
Thousands of Australians battling a debilitating form of multiple sclerosis have been granted a reprieve, as a groundbreaking ...
MIT researchers have developed a simple, low-cost technology to administer powerful drug formulations that are too viscous to be injected using conventional medical syringes. The technology, which is ...
PLYMOUTH MEETING, Pa., June 15, 2021 /PRNewswire/ -- Braeburn announces that today the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release injection for subcutaneous (SC) use (CIII ...
India-based firm Lupin has joined the pegfilgrastim parade with the FDA’s approval of Armlupeg (pegfilgrastim-unne), the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III OCARINA II trial evaluating Ocrevus® (ocrelizumab) ...
This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in one minute.
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback